Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma

NCT03190213 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT03190213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03190213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Terminated
Start date
December 4, 2017
Completion date
March 11, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors